by ComplianceQuest

Inspection Tracker

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

FDA Guidance Global Templates

Start with a Free ConsultationBook 30 minutes with a ComplianceQuest specialist.Book a Call

Sign In Create a Free Account

Big News: FDA is moving from MasterControl to ComplianceQuest.See Why

Search AgentQ/

Talk to a Specialist

Loading…

My DashboardInspection TrackerWarning LettersNaseem A. Jaffrani, M.D.

All Warning Letters

Naseem A. Jaffrani, M.D.

Warning LetterOpen

Naseem A. Jaffrani, M.D., 3311 Prescott Road, Suite 310 Alexandria , LA 71301 United StatesIssued May 4, 2026Center for Drug Evaluation and Research (CDER)

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations1

Issue DateMay 4, 2026

Product TypeDrugs

StatusOpen

Letter Details

Firm: Naseem A. Jaffrani, M.D.
Location: Naseem A. Jaffrani, M.D., 3311 Prescott Road, Suite 310 Alexandria , LA 71301 United States
FEI Number: N/A
Country: United States
Issue Date: May 04, 2026
Issuing Office: Center for Drug Evaluation and Research (CDER)
Product Type: Drugs
Status: Open

Subject

Clinical Investigator

Naseem A. Jaffrani, M.D. FDA Warning Letter, May 4, 2026